906673-81-2

Basic information

• Product Name: Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn
• Synonyms: Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn
• CAS NO: 906673-81-2
• Molecular Weight: 818.884
• Mol File: 906673-81-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(906673-81-2)
• EPA Substance Registry System: Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(906673-81-2)

Safety Data

• Hazardous Substances Data: 906673-81-2(Hazardous Substances Data)

Upstream product

• 83103-21-3 N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester 
• 2188-18-3 Boc-Arg(NO₂)-OH 
• 84308-16-7 (S)-phenylalanine benzyl ester benzene sulfonate 
• 90600-39-8 Boc-Arg(Nω-NO2)-Gly-OH 
• 138108-43-7 Boc-Asp(OBzl)-Phe-OBzl 
• 166953-02-2 Boc-Gly-Asp(OBzl)-Phe-OBzl 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 

Downstream Products

• 906673-85-6 estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 906673-91-4 estradiol-3-O-acetyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 906674-58-6 estrone-3-oxyacetyl-Arg(NO₂)-Gly-Asp(OBzl)-Phe-OBzl 
• 110697-46-6 H-Arg-Gly-Asp-Phe-OH 
• 1147835-22-0 Boc-Asp(OBn)-Phe-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 

Relevant articles and documents

RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis

Dexamethasone (Dex) is one of the most effective anti-inflammatory glucocorticoids, while the side effect, osteoporosis seriously limits its clinical use. Cell adhesion is involved in the onset of inflammation and osteoporosis, and RGD-peptides are well k

Synthesis, evaluation and 3D QSAR analysis of novel estradiol-RGD octapeptide conjugates with oral anti-osteoporosis activity

To enhance the potency, reduce the side effects and improve oral property of estradiol in estrogen replacement therapy (ERT), 6 novel estradiol-RGD octapeptide conjugates have been prepared. In an ovariectomized mouse osteoporotic model, at an oral dosage

Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol